Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastoma
- 14 December 2015
- journal article
- case report
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 33 (2) , 137-146
Abstract
Epithelioid glioblastoma (GBM) and rhabdoid GBM are rare variants that are morphologically similar, but there is no consensus on the characteristics of each disease. These tumors have aggressive features of early recurrence and leptomeningeal dissemination and tend to develop in younger patients compared to typical GBM. The prognosis is normally worse than typical GBM, even with intensive chemoradiotherapy after surgical resection. Thus, accurate diagnosis and effective therapy for epithelioid/rhabdoid GBM are required. Four consecutive patients aged 16–48 years were diagnosed with epithelioid/rhabdoid GBM by pathological and immunohistochemical analysis at Yamaguchi University Hospital from 2006 to 2012. Two of these patients had relatively long-term survival (19 and 23 months after diagnosis). Two cases had a BRAF V600E mutation, whereas no ATRX mutation was present in any cases. All patients suffered leptomeningeal and/or spinal dissemination that worsened their prognosis. These results illustrate the need for a new therapeutic approach, such as molecular targeted drug therapy like BRAF inhibition, in addition to standard chemoradiotherapy for typical GBM.Keywords
This publication has 28 references indexed in Scilit:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Rhabdoid glioblastoma in a child: case report and literature reviewBrain Tumor Pathology, 2011
- Rhabdoid glioblastoma: Case report and literature reviewNeuropathology, 2010
- Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytomaNeurology, 2009
- Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumoursBritish Journal of Cancer, 2009
- Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcomaCancer, 2008
- BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomasJournal of Clinical Investigation, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Mutations of the BRAF gene in human cancerNature, 2002